Clinical Trials Logo

Clinical Trial Summary

Statins are a group of medications that are used to lower cholesterol levels. Although serious side effects are rare, some people taking statins experience muscle pain or weakness. This study will evaluate the number of people who experience mild muscle complaints and will determine the effect of statins on skeletal muscle strength, endurance, and aerobic exercise performance.


Clinical Trial Description

Statins are the most effective medications for reducing high cholesterol levels. They are extremely well tolerated by the majority of people but can produce a variety of muscle-related side effects in some people. Of these side effects, the most serious is rhabdomyolysis, which involves muscle fiber damage that can begin as muscle pain and progress to a loss of muscle cells, kidney failure, and death. While rhabdomyolysis is extremely rare, some people experience the more common muscle-related side effects of statins, such as muscle pain (known as "myalgia"), cramps, and weakness. These more common side effects warrant attention because they may limit the use of statins, affect mobility, and increase the risk of injury in older individuals. Also, the term "muscle weakness," often used by patients and their doctors, is not well defined and can refer to a wide range of complaints from simple fatigue to an actual inability to perform activities of daily living. It is important to describe and quantify in more detail the muscle-related side effects associated with statins. The purpose of this study is to determine the incidence of statin-induced mild muscle complaints and to determine the effect of statins on skeletal muscle strength, endurance, and aerobic exercise performance.

This study will enroll healthy people who have never received statin medications. First, participants will attend three study visits over a period of 2 weeks. These study visits will include blood collection, questionnaires on physical activity and pain, vital sign measurements, and body measurements, including height, weight, and head circumference. Participants will also complete two cardiopulmonary exercise stress tests on a treadmill and will undergo arm and leg strength testing. Some participants may undergo a muscle biopsy. Participants will then be randomly assigned to receive either 80 mg of atorvastatin or placebo on a daily basis for 6 months. Blood will be collected again at Month 3. At Month 6, participants will attend two study visits for repeat baseline measurements. All participants will be contacted by phone every other week during the 6-month treatment period to monitor adverse events and medication compliance. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00609063
Study type Interventional
Source Hartford Hospital
Contact
Status Completed
Phase N/A
Start date January 2008
Completion date June 2011

See also
  Status Clinical Trial Phase
Completed NCT00199745 - Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity Phase 4
Completed NCT03979157 - Non-invasive Molecular Imaging of Muscle Structure (MSOT_muscles) N/A
Completed NCT04115475 - New Imaging Biomarkers for Muscular Diseases - Multispectral Optoacoustic Imaging in Spinal Muscular Atrophy N/A
Completed NCT03354767 - The Role of Ischaemia-reperfusion Injury in the Pathogenesis of Muscle Wasting After Thoracic Aortic Surgery N/A
Completed NCT03440034 - Study of Pioglitazone in Sporadic Inclusion Body Myositis Phase 1
Completed NCT04838509 - Diagnoses Associated With Persistent Elevation of Creatine Kinase
Completed NCT03406780 - A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy Phase 2
Completed NCT01826487 - Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Phase 3
Terminated NCT02090959 - An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy Phase 3
Recruiting NCT05126758 - A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy Phase 3
Recruiting NCT05183152 - Non-invasive BCI-controlled Assistive Devices N/A
Completed NCT03179631 - Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy Phase 3
Terminated NCT02829814 - Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia Phase 3
Recruiting NCT06226376 - Mollii Suit and Fibromyalgia (EXOFIB 2) N/A
Completed NCT03211390 - Using Telemedicine to Improve Spasticity Diagnosis Rates
Completed NCT03250988 - Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Long-Term Care Facility
Completed NCT03209960 - Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity
Terminated NCT00240981 - TOM: Testosterone in Older Men With Sarcopenia Phase 4
Completed NCT03268421 - Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia N/A
Completed NCT05730842 - Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers Phase 1